StockData

NRX Pharmaceuticals vs Ovid Therapeutics

NRXP and OVID side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NRXP and OVID compare

Ovid Therapeutics is the larger company, worth 4.1 times as much as NRX Pharmaceuticals ($434M against $106M).

NRX Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −692% compared with −2179% at Ovid Therapeutics.

Ovid Therapeutics scores higher on the StockData Score (10 against 0 for NRX Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNRXPOVID
Size and price
Market cap$106M$434M
Share price$2.45$2.22
Change, 1 year−1.6%70.1%
Change, 5 years−96.4%−31.9%
Beta (5Y)1.151.34
Employees2923
StockData Score
Total score010 (better)
Valuation score01 (better)
Growth score01 (better)
Performance score02 (better)
Health score06 (better)
Dividend score00
Valuation
P/S31.3× (better)274×
P/B–2.1×
Growth
Revenue growth (TTM)–−76.2%
Revenue growth, 5Y average–−10.5%
Profitability
Gross margin46.6%–
Operating margin−586% (better)−3687%
Net margin−692% (better)−2179%
Return on equity–−26.0%
Return on invested capital–−160%
Financial health
Debt / equity–0.00
Interest coverage−17.4×–
Current ratio0.8612.39 (better)
Altman Z-score−13.459.41 (better)
Piotroski F-score5 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions26.9%75.3%
Held by insiders15.6%13.6%
Insider net buying, 12 months–−$29.3K
Short interest, % of float28.6%10.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.